Bile acids can exert biological effects by activating or inhibiting FXR activity (Fiorucci and Distrutti, 2019; Fu et al., 2019; Liu et al., 2020), and the latter is able to adjust the liver glucose and lipid levels and inflammatory response as an important therapeutic target for NAFLD (Kim et al., 2016). This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.